ISRCTN ISRCTN15391202
DOI https://doi.org/10.1186/ISRCTN15391202
ClinicalTrials.gov (NCT) Nil known
Clinical Trials Information System (CTIS) Nil known
Integrated Research Application System (IRAS) 1007882
Protocol serial number ETH47-101, IRAS 1007882
Sponsor Ethris (Germany)
Funder Ethris GmbH
Submission date
04/12/2023
Registration date
04/12/2023
Last edited
04/12/2023
Recruitment status
No longer recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Mr Nigel Tomkinson
Scientific

Ethris GmbH
Semmelweisstrasse 3
Planegg
Munich
82152
Germany

Email info@ethris.com
Mr Nigel Tomkinson
Public

Ethris GmbH
Semmelweisstrasse 3
Planegg
Munich
82152
Germany

Email info@ethris.com
Dr Annelize Koch
Principal investigator

Simbec-Orion Clinical Pharmacology
Merthyr Tydfil Industrial Park
Cardiff Road
Merthyr Tydfil
CF48 4DR
United Kingdom

Phone +44 (0)1443 694313
Email annelize.koch@simbecorion.com

Study information

Primary study designInterventional
Study designFirst-in-human trial in healthy participants
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titlePhase 1 Trial: RD 799.35751 (ETH47-101)
Study objectivesThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Ethics approval(s)

1. Approved 22/11/2023, Wales Research Ethics Committee 2 (Wales Research Ethics Committee 2, Health and Car Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941119; Wales.REC2@wales.nhs.uk), ref: 23.WA.0186

2. Approved 22/11/2023, MHRA (MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 56586/0001/001-0001

Health condition(s) or problem(s) studiedHealthy volunteers
InterventionThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Primary outcome measure(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome measure(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date30/04/2024

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
Upper age limit55 Years
SexAll
Target sample size at registration88
Key inclusion criteriaThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Key exclusion criteriaThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Date of first enrolment29/11/2023
Date of final enrolment09/04/2024

Locations

Countries of recruitment

  • United Kingdom
  • Wales

Study participating centre

Simbec Research Limited
Simbec House Merthyr Tydfil Industrial Park
Merthyr Tydfil Industrial Park
Pentrebach 
Merthyr Tydfil
Mid Glamorgan 
CF48 4DR
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
IPD sharing planThe datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

04/12/2023: Study's existence confirmed by Wales Research Ethics Committee 2.